The report provides a detailed analysis essential for establishing a melanin-concentrating hormone production plant. It encompasses all critical aspects necessary for melanin-concentrating hormone production, including the cost of melanin-concentrating hormone production, melanin-concentrating hormone plant cost, melanin-concentrating hormone production costs, and the overall melanin-concentrating hormone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a melanin-concentrating hormone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Melanin-concentrating hormone (MCH) is a cyclic neuropeptide, having disulfide bridges, mainly utilised as a high-purity research reagent (>95%) in neuroscience, endocrinology, and metabolic studies. It is used to investigate appetite regulation, energy homeostasis, anxiety, sleep disorders, and pigmentation via its agonism of MCH-R1 and MCH-R2 receptors. Additionally, MCH analogues or antagonists are explored for potential pharmaceutical development in obesity treatments, skin lightening, or oncology.
The market growth for melanin-concentrating hormone is propelled by the global obesity epidemic and rising metabolic syndrome cases that propel R&D for antagonists targeting appetite suppression, energy metabolism, and CNS disorders like anxiety and sleep issues. Additionally, biopharmaceutical investments in neuroscience and anti-obesity therapies, boosted by robust North American/European funding and rapid Asia-Pacific expansion from urbanisation, diabetes prevalence, and healthcare spending, boost the market growth. Moreover, elevated pharma/biotech R&D budgets, demand for tools in feeding behaviour studies, and solid phase peptide synthesis scalability propel the market expansion. Industrial melanin-concentrating hormone procurement is influenced by its high cost, driven by complex solid-phase synthesis, HPLC purification, and low-volume demand.
Raw Material for Melanin-Concentrating Hormone Production
According to the melanin-concentrating hormone production plant project report, the various raw materials for melanin-concentrating hormone production include Fmoc-protected amino acids.
Production Process of Melanin-Concentrating Hormone
The extensive melanin-concentrating hormone production cost report consists of the following major industrial production process:
- Production via solid-phase peptide synthesis: The production process of melanin-concentrating hormone depends on solid-phase peptide synthesis (SPPS) for its 19-residue cyclic mammalian form (Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val-NH2). The process begins with Fmoc-protected amino acids sequentially coupled to a polystyrene resin via automated deprotection (piperidine), activation (HBTU/DIEA), and washing cycles, followed by selective N-terminal Fmoc removal. In the next step, following chain assembly, the peptide is cleaved from the resin using TFA/scavenger cocktail, precipitating the crude protected peptide. The peptide undergoes disulfide bond formation between Cys7 and Cys¹6 via air oxidation (pH 8.3) or DMSO/I2 methods to form the critical ring structure. The final steps involve purification by reverse-phase HPLC to >95% purity verified by analytical HPLC and mass spectrometry, lyophilisation into stable white powder, and final QC with COA for research-grade release.
Properties of Melanin-Concentrating Hormone
Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid neuropeptide with the human/mouse/rat sequence Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val-NH2 (molecular formula C105H159N27O31S2). It has a disulfide bridge between Cys7 and Cys¹6 that stabilises its ring structure essential for receptor binding. Its molecular weight is 2386.8 Da, appearing as a white lyophilised powder soluble in water, DMSO, or acidic buffers (>1 mg/mL at neutral pH). It shows stability up to 1-2 years at -20 degrees Celsius but is prone to degradation via oxidation of Met residues or hydrolysis if not stored lyophilised. It is amphipathic with a hydrophobic C-terminal tail and basic Arg residues (pI ~8.5), enabling G-protein coupled receptor agonism. Its physical properties include a compact folded conformation (via NMR/CD spectroscopy showing α-helix in ring region) and biological half-life of minutes in vivo due to peptidase cleavage.